IMMUTEP OPERATIONAL UPDATE
• AIPAC reaches ~72% of events and TACTI-002 recruitment is progressing well
• New data from TACTI-002 and INSIGHT-004 to be reported at ASCO in June 2021
• TACTI-003 clinical trial design enables evaluation of efti in 1st line recurrent or metastatic HNSCC
patients to better understand its effect in combination with pembrolizumab
• Robust financial position with cash runway into calendar year 2023, beyond several significant data
read-outs
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $350.4M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 23.8¢ | $114.8K | 478.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 316924 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 329249 | 22 |
View Market Depth
| Last trade - 12.58pm 14/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |